from yesterday's financial release:

Corporate Development and Strategic Partnering
In addition, the Company has entered into a Material Transfer Agreement for the evaluation of its technology in combination with another novel technology for CNS disorders and is in advanced negotiation for two additional Material Transfer Agreements.
 
The Company is currently focused on securing financing via additional strategic partnership transactions for its xB3 drug delivery platform.
 
Strategy and Pipeline
Our goal is to become the leading blood-brain barrier drug delivery company, enabling the treatment of patients with previously untreatable brain diseases by improving the delivery of existing medicines into the brain. To achieve this goal, we are pursuing the following strategic actions, subject to securing longer term funding:
• Advance the development of our xB3 -001 program.
• Advance our xB3 -007 pipeline programfor the treatment of Gaucher’s disease and other GBA1 gene mutation associated conditions including Parkinson’s disease and Lewy body dementia.
• Advance our xB3-004 pipeline program for the treatment of conditions mediated by the cytokine interleukin 1, or IL-1, including neuropathic pain and pain associated with auto-inflammatory conditions and Fabry disease and brain inflammation in Multiple Sclerosis.
• Advance our new xB3 -009 pipeline program targeting Frontotemporal Lobe dementia, or FTD, the lysosomal storage disorder neuronal ceroid lipofusinosis and amyotrophic lateral sclerosis, or ALS or Lou Gehrig’s disease, through the delivery of xB3-Progranulin.
• Forge Additional Strategic Partnerships for our xB3 Platform Technology.
 
Our Licensing Model
We believe that our licensing business model has the potential to generate considerable value for shareholders as licensed programs progress through development milestones. We will report material milestones as appropriate.
 
Outlook
Following a positive response by the FDA to the Company’s pre-IND submission, the Company continues to pursue multiple new sources of capital financing, as well as licensing and partnership agreements to provide working capital to support the progression of xB3-001 as a treatment for HER2+ breast cancer and brain metastases.
 
Bioasis is also focused on the use of its technology to restore lysosomal function, reduce brain inflammation and offer disease modifying potential for neurodegenerative conditions. To this end, Bioasis has built an asset rich pipeline of innovative product candidates. The Company is currently pursuing further work on these preclinical Pipeline Programs, including xB3 -004 (pain, CNS inflammation and neurodegeneration), xB3 -007 (Gaucher’s disease, Parkinson’s disease and Lewy body dementia) and xB3-Progranulin for the treatment of Frontotemporal Lobe dementia, ALS and neuronal ceroid lipofusinosis, with the intention of strengthening our platform, creating greater value for our intellectual property and building stronger licensing partnerships. 
 
We further anticipate that there will be additional recognition of the strength of the Company’s intellectual property portfolio as the Company executes its strategy.
 
The Company continues to pursue and progress strategic partnering discussions for the xB3 platform. Building on our current partnerships, we anticipate that additional partnerships may be transacted in 2021, with funds from upfront payments being invested in the pipeline.